Breaking News
Ad-Free Version. Subscribe now to follow markets, faster and distraction-free. Upgrade now
0
Ad-Free Version. Subscribe now to follow markets, faster and distraction-free. More details

2 Medical Technology Stocks Set To Benefit From An Aging Global Population

By Investing.com (Tezcan Gecgil/Investing.com )Stock MarketsDec 23, 2020 09:04
ng.investing.com/analysis/2-medical-technology-stocks-set-to-benefit-from-an-aging-global-population-48482
2 Medical Technology Stocks Set To Benefit From An Aging Global Population
By Investing.com (Tezcan Gecgil/Investing.com )   |  Dec 23, 2020 09:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Stocks of medical technology firms manufacturing and marketing health-care products have had a mixed year. In the wake of the outbreak of the coronavirus pandemic, elective surgeries have been delayed or even cancelled in many countries.

As the rollout of vaccines into 2021 brings more normality to our lives, as well as to the healthcare sector, two UK-headquartered global companies may pique investor interest: Smith & Nephew (LON:SN), (NYSE:SNN) and ConvaTec (LON:CTEC), (OTC:CNVVY).

We believe the long-term growth possibilities for each remains upbeat in a post-COVID world. According to metrics from the United Nations:

"Virtually every country in the world is experiencing growth in the number and proportion of older persons in their population... [B]y 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%)."

Similarly, the UK's Office for National Statistics suggests:

"In 50 years’ time, there are likely to be an additional 8.6 million people aged 65 years and over – a population roughly the size of London.”

1. Smith & Nephew

Headquartered in Watford, Smith & Nephew is listed on the FTSE 100. Its operations extend to more than 100 countries, where it employs close to 18,000 people. In 2019, annual sales were $5.1 billion (or £3.8 billion).

The company focuses on three segments:

  • Orthopedics;
  • Sports medicine and ear, nose and throat (ENT);
  • Advanced wound care.

SN stock currently trades 15% lower than at the start of the year. On Dec. 22, it closed at 1,556.5p. ($41.85 for U.S.-based shares). The current price supports a dividend yield of about 2.1%.

Smith & Nephew Weekly Chart.
Smith & Nephew Weekly Chart.

In late October, the group announced third-quarter metrics. Revenue came at $1.2 billion (£900 million), down 3.7% YoY. Management noted that the number was a significant recovery from the Q2 underlying decline of 29.3%.

The U.S. market, which returned to growth, was up 0.9% YoY. However, other than China, which also grew, emerging markets were in decline.

CEO Roland Diggelmann said:

"I am pleased with our progress in the third quarter ... [A]s global levels of elective surgery recovered [we] delivered a substantial improvement in performance over the previous quarter, led by growth in both the U.S. and China, our two largest markets."

SN stock's forward P/E and P/S ratios are 20.49 and 3.91, respectively. Although we like the shares, given the likelihood of a possible third wave of the pandemic across the world, we'd wait to invest, at least until the release of Q4 results in late January. A potential decline of 5%-7% would improve the margin of safety and make the valuation more attractive.

An aging population in many of its main markets as well as increased health-care spending in emerging markets are likely to provide tailwinds for Smith & Nephew in future quarters.

2. ConvaTec

Reading-based FTSE 250 member, medical technology group ConvaTec specializes in the management of chronic conditions. It is well-known for products that focus on advanced wound care, ostomy care (for the removal of body waste), continence, critical care and infusion care (or intravenous therapy).

ConvaTec employs more than 9,000 individuals globally, and in 2019 it generated revenues of $1.83 billion (£1.37 billion).

Since the start of the year, CTEC stock has returned over 8%. On Nov. 22, the shares closed at 202.6p. ($11.15 for U.S.-based stock). The dividend yield stands at 2.3%.

Convatec Weekly Chart.
Convatec Weekly Chart.

Management provided a trading update in late October. Revenue was $493 (£369) million, up 6.5% YoY. Despite the revenue increase, the pandemic continued to affect the Advanced Wound Care and Critical Care segments.

CEO Karim Bitar, who was pleased with the results, commented:

"We continued to respond well to stronger than anticipated customer and patient demand, particularly in our infusion care and continence and critical care businesses. We now expect to deliver revenue growth at the higher end of our guidance range and to exceed our previous margin guidance for 2020."

CTEC stock's forward P/E and P/S ratios are 2.05 and 3.00, respectively. Like SN stock, we believe CTEC shares could be appropriate for long-term portfolios. Potential investors could consider buying the dips.

2 Medical Technology Stocks Set To Benefit From An Aging Global Population
 

Related Articles

2 Medical Technology Stocks Set To Benefit From An Aging Global Population

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email